
원료의약품
Sildenafil Citrate (실데나필시트르산염)
KDMF APIs
Sildenafil Citrate
품목명 (한글) | 실데나필시트르산염 |
|---|---|
분류 | 비뇨생식기관 및 항문 |
CAS No. | 171599-83-0 |
KDMF 등록번호 | 20200602-211-J-644 |
제조원 | Mylan Laboratories Limited |
규격 | EP |
품목 정보
IUPAC Name | Piperazine,1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-,2-hydroxy-1,2,3-propanetricarboxylate (1:1) |
|---|---|
Synonyms | 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate (1:1) 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one citrate 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate |
Description | When NO is locally released from sexual stimulation, sildenafil inhibits PDE5 and increases the amount of cGMP in the corpus cavernosum, which relaxes smooth muscles and increases blood flow into the corpus cavernosum, producing an erection. Recommended dose of sildenafil has no effect in the absence of sexual stimulation. PDE5 is present in other tissues including platelets, abdominal smooth muscle, skeletal muscle, which may be the basis for inhibition of platelet thrombogenesis and peripheral arteriovenous dilatation. |
Certificate of Analysis | If you need more information, please contact us. |
규격서·시험성적서 등 추가 자료가 필요하시면 문의 시 함께 요청해 주세요. 담당자가 확인 후 회신드립니다. (02-579-1056 · ace@acebiopharm.com)